The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

London pre-open: Positive start expected after record close on Wall Street

Tue, 03rd Mar 2015 07:50

UK stocks are expected to open with modest gains on Tuesday following a decent performance on Wall Street the night before, as investors watch corporate earnings on a quiet day for economic data.City sources predict the FTSE 100 will open 10 points higher than Monday's close of 6,940.64.Both the Dow Jones and S&P 500 closed at record highs the previous session, while the Nasdaq Composite finished above 5,000 for the first time in 15 years.Following a barrage of economic indicators released on Monday, Tuesday's session is looking pretty quiet, with German retail sales and the Eurozone producer price index being the only major releases.Stocks to watchCost saving initiatives helped Barclays grow its annual pre-tax profit by 12% last year, but the bank set aside £1.25bn for provisions to cover litigation costs related to ongoing probes into misconduct and rigging foreign exchange rates.Commodities trader and mining group Glencore managed to meet City expectations with a 2% decline in operating profits in 2014 as strong earnings growth in its marketing division was outweighed by falling prices dragging on its industrial business. It also said that in response other volatile backdrop for commodities markets, the capital expenditure budget for 2015 has been cut to $6.5bn-6.8bn from previous guidance of $7.9bn.Housebuilder Taylor Wimpey has doubled its dividend payment after unveiling impressive profits growth in 2014 and enjoying better-than-expected trading in the new year. On revenue up 17% to £2.69bn, the FTSE 100 group drove a 68% increase in profit before tax and exceptional items to £450.1m and proposed a near tripling in the final dividend to 1.32p per share.AstraZeneca has completed its acquisition of the rights to Activis' branded respiritory business in the US and Canada. AstraZeneca has paid Actives $600m of initial consideration as well as an extra $100m for a number of contractual consents and approvals.

Related Shares

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.